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Abstract
Background: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a pro-inflammatory cytokine with
growth factor–like properties for monocytes and dendritic cells (DCs). In the present study, serum GM-CSF
levels and the activation status of DCs were studied in type 2 diabetes mellitus (T2DM) subjects.
Methods: Study subjects were recruited from the Chennai Urban Rural Epidemiology Study. Healthy controls
(n= 45) and T2DM patients (n = 45) were included in the study. Serum levels of GM-CSF, interleukin-1b, inter-
leukin-6, and tumor necrosis factor-a were measured. Enumeration of circulating DCs (myeloid [m] and plas-
mocytoid [p]) and its surface antigen expression were quantified by flow cytometry.
Results: The serum GM-CSF levels were significantly higher among diabetes subjects compared with subjects
without diabetes and showed a positive correlation with glycated hemoglobin (r = 0.208, P= 0.018). The serum
GM-CSF levels were lower in subjects on combined insulin and oral hypoglycemic agents (OHA) treatment
(1.09 pg/mL) compared with those taking OHA alone (1.9 pg/mL). The increased GM-CSF levels were associ-
ated with the activated phenotype of mDCs and pDCs, as determined by up-regulation of the lineage markers.
Conclusion: The activated state of mDCs and pDCs seen among diabetes subjects might be due to the increased
levels of GM-CSF and other pro-inflammatory cytokines.
Introduction
Type 2 diabetes mellitus (T2DM) is characterized by achronic, low-grade inflammation with increased circula-
tory levels of pro-inflammatory cytokines. During early
stages of the disease, the inflammation is more organ-specific,
affecting the target organs of insulin (adipose tissue, liver, and
skeletal muscle) leading to insulin resistance.1 With disease
progression, inflammation becomes more systemic and con-
tributes to the microvascular complications seen in diabe-
tes.2,3 The role of pro-inflammatory cytokines like tumor
necrosis factor-a (TNF-a) and interleukin (IL)-6 in diabetes-
associated inflammation and insulin resistance is well estab-
lished.4–7 However, the role of granulocyte-macrophage
colony-stimulating factor (GM-CSF), a pro-inflammatory cy-
tokine with growth factor–like properties, is less well studied.
GM-CSF has been shown to promote maturation of myeloid-
lineage cells like granulocytes and macrophages in vivo.8,9 It
is readily induced by the pro-inflammatory cytokines like
TNF-a, IL-6, and IL-1b and in turn induces the secretion of
these cytokines, creating a vicious cycle. Apart from its im-
mune-related functions, GM-CSF has been shown to play a
central role in food intake and insulin resistance in animal
models.10
The most important function of GM-CSF in the immune
system is its ability to generate dendritic cells (DCs) from
myeloid progenitor cells. DCs serve as a first line of defense
mechanism, polarizing the T helper (Th) cells and thereby
linking innate and adaptive immunity.11,12 In diabetes, con-
ventional DCs polarize the Th cells toward pathogenic Th1
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cells (which induce insulin resistance), whereas the tolero-
genic DCs polarize them toward protective T-regulatory
cells.13 In the present study, the serum levels of GM-CSF and
the activation state of peripheral DCs were studied in T2DM
subjects.
Subjects and Methods
Study subjects
The study subjects were recruited from the Chennai Urban
Rural Epidemiological Study (CURES), an ongoing epidemi-
ological study conducted on a representative population (‡ 20
years old) of Chennai (formerly Madras), the fourth largest
city in India. The methodology of the study has been pub-
lished elsewhere.14 In brief, in Phase 1 of the urban component
of CURES, 26,001 individuals were recruited based on a sys-
tematic sampling technique with random start. Fasting cap-
illary blood glucose was determined using the OneTouch
Basic glucometer (Lifescan, Johnson & Johnson, Milpitas, CA)
in all subjects. Details of the sampling are described on our
website (www.drmohansdiabetes.com/bio/WORLD/pages/
pages/chennai.html). In Phase 2, detailed studies of diabetes
complications, including nephropathy and retinopathy, were
performed, and in Phase 3, every 10th individual in Phase 1
was invited to participate in more detailed studies. For the
present study, the following groups were randomly selected
from Phase 3 of CURES using computer-generated random
numbers as follows: Group 1, normal glucose tolerance (NGT)
subjects (n = 45); and Group 2, T2DM subjects (n= 45).
The inclusion criteria were patients within the normal
range of white blood cell count (4.0–10.0 · 103/mL) to mini-
mize the confounding effect of infection. The exclusion criteria
were smoking, alcohol intake, and patients presenting with
symptoms suggestive of type 1 diabetes defined as history of
diabetic ketoacidosis, heavy ketonuria (3+ ), continuous re-
quirement for insulin within 1 year of diagnosis, and poor
insulin reserve as shown by C-peptide.15 Also, patients with a
previous diagnosis of urolithiasis, liver cirrhosis, congestive
heart failure, chronic lung diseases, chronic infections, viral
hepatitis, or any known renal diseases were excluded. In-
stitutional ethical committee approval was obtained for the
study, and written informed consent was obtained from all
the study subjects.
Anthropometric and biochemical measurements
Anthropometric measurements including height, weight,
and waist circumference were obtained using standardized
techniques as detailed elsewhere.14 Blood pressure was re-
corded using a mercury sphygmomanometer (Deluxe BP
apparatus, Diamond, Pune, India). Two readings were
taken 5min apart, and the mean of the two was taken as the
blood pressure. Fasting plasma glucose (glucose oxidase–
peroxidase method), serum cholesterol (cholesterol oxidase–
peroxidase–amidopyrine method), serum triglycerides
(glycerol phosphate oxidase–peroxidase–amidopyrinemethod),
and high-density lipoprotein cholesterol (direct method;
polyethylene glycol–pretreated enzymes) were measured
using a Hitachi-912 autoanalyzer (Roche Diagnostics, Basel,
Switzerland). The intra- and inter-assay coefficients of varia-
tion for the biochemical assays ranged between 3.1% and
7.6%. Low-density lipoprotein cholesterol was calculated
using the Friedewald formula. The plasma concentrations of
high-sensitivity C-reactive protein were measured by nephe-
lometric assay. Leukocyte count was assessed using flow cy-
tometry (model SF-3000, Sysmex, Kobe, Japan). In-kit quality
controls were within an acceptable range.
Determination of cytokine levels by multiplex assay
The levels of cytokines (IL-1b, IL-6, TNF-a, and GM-CSF) in
undiluted serum were estimated by the Bio-Plex multiplex
cytokine assay system (Bio-Rad, Hercules, CA). The detection
limits for the various cytokines were as follows: IL-1b, 2.7 pg/
mL; IL-6, 2.31 pg/mL; TNF-a, 4.89 pg/mL; and GM-CSF,
0.67 pg/mL.
Flow cytometry
Peripheral blood cells (fromNGT and T2DMpatients) were
incubated with DC lineage marker-specific monoclonal anti-
body at saturating concentrations. Red blood cells were lysed
with BD lysing solution (BD Biosciences, San Jose, CA). The
mouse anti-human monoclonal antibodies used in this study
were fluorescein isothiocyanate–labeled anti-Lin (CD3, CD14,
CD16, CD19, CD20, and CD56), allophycocyanin-labeled
anti-CD11c, phycoerythrin-labeled anti-CD123, and peridinin-
chlorophyll-protein-complex-labeled anti-HLA-DR. Mono-
clonal antibodies specific for the lineage markers Lin 1,
HLADR, CD11c, and CD123 were used in all samples to gate
on myeloid DCs (mDCs) and plasmocytoid DCs (pDCs). For
analysis, 100,000 events were acquired per tube using a BD
FACSCanto cytometer (BD Biosciences). Compensation
was performed using BD CompBeads (BD Biosciences) for
single-color controls, and unstained cells were used as nega-
tive controls. Datawere analyzed using FlowJo software (Tree
Star, Ashland, OR). Nonviable cells were excluded from
analysis on the basis of forward and side scatter.
Statistical analysis
Student’s t test and one-way analysis of variance were used
to compare groups for continuous variables; the Mann–
Whitney t test were used for parameters that did not show
normal distribution. All the analyses were done using SPSS
statistical package version 15.0 (SPSS, Chicago, IL) or
GraphPad Prism version 5.0 (GraphPad, San Diego, CA),
and in all comparisons a value of P < 0.05 was considered
significant.
Results
Table 1 shows the clinical and biochemical characteristics of
the study subjects. Both the control and diabetes subjects were
age and gender matched. The bodymass index, systolic blood
pressure, diastolic blood pressure, fasting plasma glucose,
glycated hemoglobin, insulin resistance by homeostasis
model of assessment, and high-sensitivity C-reactive protein
levels were significantly higher in T2DM subjects compared
with NGT subjects. All the diabetes subjects were receiving
treatment. Eighty percent of the diabetes subjects were taking
oral hypoglycemic drugs, whereas the remaining 20% were
taking insulin and oral hypoglycemic drugs.
Next we estimated the levels of GM-CSF and other pro-
inflammatory cytokines in NGT and T2DM subjects. The level
of GM-CSF was significantly elevated in T2DM (geometric
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mean, 1.28 pg/mL) compared with NGT subjects (geometric
mean, 0.69 pg/mL) (P = 0.009) (Table 1). When the T2DM
subjects were stratified based on glycemic control, GM-CSF
levels were higher in those with poor control (glycated he-
moglobin > 7%) (P = 0.03) compared with those with good
glycemic control (glycated hemoglobin £ 7%). Apart from
GM-CSF, IL-1b, IL-6, and TNF-a levels were also significantly
elevated in T2DM subjects compared with the NGT group
(Table 1). GM-CSF levels showed significant correlation with
IL-1b (r = 0.374, P < 0.001), IL-6 (r= 0.468,P < 0.001), and TNF-a
(r= 0.639, P < 0.001) levels.
Next the effect of drug regimen on serum GM-CSF
levels was studied (Supplementary Fig. S1; Supplementary
Data are available online at www.liebertonline.com <http://
www.liebertonline.com >/dia). Of the 45 T2DM subjects, 36
were taking oral hypoglycemic agents (OHAs), and nine
were taking both insulin and OHA treatment. Subjects
who were on insulin +OHA combination treatment had
lower levels of GM-CSF compared with those taking
OHAs only, even though the difference was not statistically
significant.
Wenext enumerated bothmDCs andpDCs in the peripheral
blood of NGT and T2DM subjects. The non-DC population
was excluded based on lineage-positive (CD3+ , CD14+ ,
CD16+ , CD19+ , CD20+ , and CD56+ ) gating. The mDC subset
was identified by gating onCD11c+ HLA- DR+ cells, whereas
pDCswere identified as CD123+ HLA-DR+ cells (Fig. 1a and b
and Supplementary Fig. 2). We found that CD11c+ mDC
population constitutes the vast majority of the total DC pop-
ulation in all groups. In spite of T2DM subjects having signif-
icantly high levels of serum GM-CSF, no significant difference
was noted in the percentage of mDCs and pDCs between the
groups: for mDCs, NGT and T2DM geometric mean, 5.16%
and 5.32%, respectively (P= 0.80); for pDC, NGT and T2DM
geometric mean, 1.22% and 1.54%, respectively (P= 0.73)
(Table 1). No major difference was seen between the insulin+
OHA and OHA-alone treatment groups with respect to DC
count.
Next, themean fluorescence intensity of the surface antigens
on the two DC subsets was studied. Modest up-regulation of
CD11c was observed in the mDCs of T2DM subjects, even
though it did not attain statistical significance (Fig. 1c). Sig-
nificant up-regulation of CD123 was noted on the pDCs of
T2DM subjects comparedwithNGT subjects: NGT and T2DM
mean fluorescence intensity, 112.6 and 197.1, respectively
(P= 0.002) (Fig. 1e). HLA-DR was significantly up-regulated
in both mDCs (Fig. 1d) and pDCs (Fig. 1f) in T2DM subjects
compared with NGT subjects: NGT and T2DM mDC-HLA-
DR mean fluorescence intensity, 108.3 and 194.2, respectively
(P= 0.006); NGT and T2DM pDC-HLADR mean fluorescence
intensity, 83.5 and 122.6, respectively (P = 0.009) (Table 1).
Again, no major difference was seen between the insulin +
OHA and OHA-alone treatment groups with respect to ex-
pression of DC markers.
Table 1. Clinical Characteristics of the Study Subjects
Parameter NGT (n = 45) T2DM (n = 45) P
Age (years) 40.0 – 13.7 41.0 – 13.5 0.9
Gender (M/F) (n) 23/22 23/22 1.000
Body mass index (kg/m2) 22.6 – 4.3 27.0 – 5.1 < 0.001
Diabetes duration (years) — 9.5 – 6.7 —
Blood pressure (mm Hg)
Systolic 119.4– 22.5 127.1– 15.8 0.031
Diastolic 72.0 – 11.5 79.9 – 9.1 0.002
Fasting plasma glucose (mg/dL) 84.7 – 9.2 163.0– 70.9 < 0.001
Glycated hemoglobin (%) 5.3 – 0.4 8.3 – 1.9 < 0.001
hs-CRP (mg/L) 1.39 – 2.0 4.65 – 3.94 < 0.001
HOMA-IRa 1.8 – 1.2 4.1 – 2.7 < 0.001
Treatment (%)
OHA — 80
OHA + insulin — 20
Serum cytokines (pg/mL)
GM-CSF 0.69 (0.44–10.28) 1.28 (0.01–560.0) 0.009
TNF-a 5.27 (4.92–13.56) 5.40 (1.01–122.3) 0.035
IL-6 3.03 (2.2–27.9) 17.8 (0.06–12,222.0) < 0.001
IL-1b 1.87 (0.1–31.24) 2.28 (0.1–2,256.0) 0.036
DC count (%)
mDC 5.2 5.3 0.80
pDC 1.2 1.5 0.73
Surface antigens (MFI)
mDC-CD11c 274.7 341.4 0.346
mDC-HLADR 108.3 194.2 0.006
pDC-CD123 112.6 197.1 0.002
pDC-HLADR 83.5 122.6 0.009
Data are mean– SD values, geometric mean (range) values, or geometric mean as indicated. P values were adjusted for age.
aSubjects taking insulin were excluded for calculation of insulin resistance using the insulin resistance by homeostasis model of assessment
(HOMA-IR) formula.
DC, dendritic cell; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin; mDC, myeloid dendritic cell; MFI, mean
fluorescence intensity; NGT, normal glucose tolerance; OHA, oral hypoglycemic agents; pDC, plasmocytoid dendritic cell; T2DM, type 2
diabetes mellitus; TNF-a, tumor necrosis factor-a.
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FIG. 1. Representation of the gated analysis done to identify the myeloid and plasmocytoid dendritic cell populations in
peripheral blood leukocytes from normal glucose tolerance (solid lines) and type 2 diabetes mellitus (dotted lines) subjects.
Lin - (CD3 - , CD14 - , CD16 - , CD19 - , CD20- , and CD56 - ) cells were gated to identify the (a) HLA-DR +/CD11c + double-
positive myeloid dendritic cell and (b) HLA-DR +/CD123 + double-positive plasmocytoid dendritic cell populations. His-
togram analysis shows (c) near-normal expression of CD11c on myeloid dendritic cells, (d) increased expression of HLA-DR
on myeloid dendritic cells, and increased expression of both (e) CD123 and (f) HLA-DR on plasmocytoid dendritic cells in
diabetes subjects. The gray area represents the isotype control. APC, allophycocyanin; PE, phycoerythrin; PerCP, peridinin-
chlorophyll-protein-complex.
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Discussion
Even though few previous reports have looked at periph-
eral DC count in T2DM, until now the role played by GM-CSF
in T2DM and its association with peripheral DC count has not
been addressed.16–19 The current study provides three novel
findings: (1) T2DM subjects had significantly high levels of
serum GM-CSF compared with NGT subjects, which corre-
lated well with glycated hemoglobin. On attaining good
glycemic control, the GM-CSF levels tend to decrease toward
normal values. (2) In diabetes subjects, the level of GM-CSF
was lower in those who were taking OHAs + insulin com-
pared with those taking OHAs alone. (3) The increase in se-
rum GM-CSF levels was associated with a parallel increase in
the partial activation state of DCs. It is well known that insulin
has anti-inflammatory properties,20 and decreased levels of
GM-CSF in the insulin+OHA treatment group compared
with those taking OHAs alone is expected.
GM-CSF is well known for its ability to increase DC mat-
uration and function.8,9 In our study, the systemic increase in
GM-CSF levels was associated with activation of both pDCs
and mDCs as determined by the up-regulation of most of the
lineagemarkers. In parallel with the increased serumGM-CSF
levels, partial activation state of DCs was also observed. Our
results are in agreement with those of Summers et al.,16 who
reported near normal numbers of both mDCs and pDCs
among diabetes subjects. In contrast, Corrales et al.17 reported
increased levels of both mDCs and pDCs, whereas others
have reported reduced numbers under diabetes condi-
tions.18,19 However, no data are available on the high-risk
Indian population. In general, all the studies have reported
poor expression of cytokines in DCs following stimulation
under diabetes conditions. Overall, our study and other
studies report malfunctioning of DCs in T2DM subjects,
which might be a potential contributing factor for reduced
immunity toward infections in diabetes.
In our study, diabetes subjects have awide range of cytokine
values, which has already been reported by us and others.21
There could be several reasons for these variations: (1) The
diabetes population included both obese and lean diabetes
subjects, and it is well known that the immune profiles in
these two groups are different. (2) All the diabetes subjects
were receiving treatment, and hence differences in the treat-
ment modalities could also account for these wide varia-
tions.22 (3) Finally, the duration of diabetes varied from 1
month to 32 years in the diabetes mellitus group, and it is well
known that the duration of diabetes can in fact affect the cy-
tokine profile.23 Our study was a cross-sectional one, so it is
not possible to discern cause and effect using this study de-
sign. The significance of the study is that for the first time, the
role played by GM-CSF in T2DM was studied under ex vivo
conditions and was correlated with DC maturation in a high-
risk ethnic population for diabetes. The increased serum
GM-CSF along with other pro-inflammatory cytokines (TNF-
a, IL-1b, and IL-6) might account for the activated state of
mDCs and pDCs seen among diabetes subjects.
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